Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Economy
In reply to the discussion: STOCK MARKET WATCH - Thursday, 22 March 2012 [View all]Demeter
(85,373 posts)6. Top court rules against two diagnostic patents
http://www.reuters.com/article/2012/03/20/us-mayo-prometheus-patent-idUSBRE82J0NV20120320
The Supreme Court rejected two patents on a method for monitoring a patient's blood to determine the best drug dosage, a decision that may affect the profitability of personalized medicine.
The justices unanimously overturned on Tuesday a ruling by a U.S. appeals court that allowed the patents for Nestle SA unit Prometheus, the high court saying companies could not patent observations about a natural phenomenon.
The patent challenge, brought by a unit of the Mayo Clinic, had been closely watched because it could affect the burgeoning field of personalized medicine, which can also involve determining whether a patient is genetically susceptible to a disease or which patient would respond best to which treatment.
The Supreme Court's opinion, written by Justice Stephen Breyer, concluded that Prometheus' process for monitoring a patient, and adjusting dosage as needed, was not patent-eligible.
AND NOW, BIG PHARMA IS SHOCKED...SHOCKED, I SAY, THAT THEIR BRIBES DIDN'T SUFFICE TO CARRY THE DAY...
The Supreme Court rejected two patents on a method for monitoring a patient's blood to determine the best drug dosage, a decision that may affect the profitability of personalized medicine.
The justices unanimously overturned on Tuesday a ruling by a U.S. appeals court that allowed the patents for Nestle SA unit Prometheus, the high court saying companies could not patent observations about a natural phenomenon.
The patent challenge, brought by a unit of the Mayo Clinic, had been closely watched because it could affect the burgeoning field of personalized medicine, which can also involve determining whether a patient is genetically susceptible to a disease or which patient would respond best to which treatment.
The Supreme Court's opinion, written by Justice Stephen Breyer, concluded that Prometheus' process for monitoring a patient, and adjusting dosage as needed, was not patent-eligible.
AND NOW, BIG PHARMA IS SHOCKED...SHOCKED, I SAY, THAT THEIR BRIBES DIDN'T SUFFICE TO CARRY THE DAY...
Edit history
Please sign in to view edit histories.
82 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
RecommendedHighlight replies with 5 or more recommendations
Thanks for following up on that, Po. It plays into Tansy's "shocked, shocked!" theme, too!
Demeter
Mar 2012
#3
Greece’s international creditors say risk-prone program may lead to missing 2020 debt target
Demeter
Mar 2012
#7
IS THIS WHY? Fool’s gold behind Beijing loan guarantees Firm accused of ‘wealth management’ schemes
Demeter
Mar 2012
#32
indeed. -- now NC isn't Mich -- but i certainly had the heat cut on in the mornings
xchrom
Mar 2012
#18
"US Senators roll call votes correlate strongly with the opinions of their rich constituents"
bread_and_roses
Mar 2012
#40